Funder profile: Cambridge Capital Group
Cambridge Capital Group (CCG) is a leading business angel group that has been investing in hi-tech businesses for more than 10 years. It formed in the autumn of 2000 and has been backing technology start-ups in the region since then. Members have invested several millions of pounds into more than 25 live portfolio companies in the Cambridge technology cluster.
CCG offers development funding for early stage technology based companies in the pre-eminent regional technology market in the UK, from a group of business angels. Non technology companies are considered occasionally but only if they come recommended by CCG’s network of members.CCG is a private syndicate of angel investors and has been active since its first investment in early 2001, although the founders have been successful private investors in technology start-ups since the mid-1990s.The founders of Cambridge Capital Group backed Bookham Technology and nCipher in early funding rounds, both of which floated very successfully on the London Stock Exchange in 2000. Successes include ITM Power and Bango, both listed on AIM, and DanioLabs, sold to Summit Plc. Most recently portfolio company, Phonetic Arts, announced that it was being acquired by Google in December 2010. Cambridge Capital Group is well integrated into the early-stage investment scene. It co-invests with the leading private and institutional technology investors and enjoya a deal flow from a range of sources, including the members' own networks in South East England and East Anglia.It seeks strong propositions at seed or start-up stage in hi-tech sectors, usually based on the physical sciences; its investors are looking for disruptive technologies with large niche or broad international markets. However, it will consider non-technology projects if they are well differentiated with attractive markets and come recommended from one of the members or the lead investor.
3T Technologies Ltd - www.3ttechnologies.comBased in Chelmsford, 3T Technologies researches, designs, and develops transparent thin film transistor technology for microelectronic devices and products. Its applications include invisible circuitry, flat panel and flexible displays, and electronics. The company was incorporated in 2004. 3T Technologies is focusing on the research and development of manufacturing processing solutions for the patterning of thin film devices and circuits. The core of this activity is based on a highly versatile macro/micro patterning technology brings the potential for achieving low cost patterning over large area substrates based on a simple manufacturing approach using peelable masking. The peelable mask patterning platform provides versatility through the range of materials and patterning methods that can be applied to provide a unique manufacturing solution. 3T has particular interest in developing patterning solutions for a range of industrial applications including for low temperature deposited oxide semiconductor coatings as applied to transparent microelectronic and photonic applications.
Augmentra - www.augmentra.comCambridge-based Augmentra delivers innovative solutions that maximise the opportunities offered by the convergence of mobile phone, imaging, and GPS technologies. Existing location-based applications have focused on urban and street navigation. Augmentra's solutions are specifically created to match the needs of the active outdoor enthusiast - whether tourist, walker, cyclist, or sailor - and to overcome the issues created by using mobile technology in a rural environment. Its ViewRanger product was awarded by Ordnance Survey as Most Innovative Product in the Navigation Sector 2007-08 and named by Nokia as Best Location-Aware Service & Application in Nokia's S60 Global Challenge 2006. In addition to ViewRanger, Augmentra develops smartphone applications for its partners in the international travel and leisure markets. Clients include AA Publishing, Ordnance Survey Ireland, and Star-Apic S.A. Augmentra also works with content owners and publishers to bring their content to the mobile market. Mike Brocklehurst and Craig Wareham, two long-time colleagues with substantial experience in the development, sales and marketing of successful software applications, founded the business in 2006.
Base 4 Innovation - www.base4innovation.co.ukBased in Cambridge, Base 4 is collaborating strongly with the NanoPhotonics Centre in the University of Cambridge, developing platforms for high-speed single molecule detection for healthcare and the life sciences. It is seeking motivated postdoctoral physicists and engineers with experience in solid state nanofabrication including electron beam lithography, focused ion beam milling, and chemical etching.
Camfridge - www.camfridge.comCamfridge is developing a platform technology for use in key target applications, each with our core gas-free high-efficiency technology embedded inside. These applications will be highly differentiated in the marketplace and better meet end-user needs, leading to growth of market share and unique brand positioning. High efficiency is of importance across the industry, but of critical importance in air conditioning where the 50 per cent reduction in energy consumption of Camfridge technology has maximum benefit. There are other unique aspects of Camfridge technology that are attractive:-1. In commercial refrigeration a key cost is maintenance caused by leakage of refrigerant. By eliminating gases this maintenance cost will be removed.2. In domestic refrigeration low noise is valuable; elimination of gases compression reduces noise.3. Redesign of applications to use lower cost components and simultaneously offer end-users systems that better meets their needs (e.g. larger internal volumes in domestic fridges).
Featurespace - www.featurespace.co.ukFeaturespace is an analytics software product company focused on profiling online customer activity and predicting future individual behaviour. The personalised insights it generates drive applications such as fraud detection and estimation of customer lifetime value. It delivers measureable business value to customers in many ways including reducing fraud losses and driving incremental revenue through the pinpointing of premium customers and individualising customer relationship strategies. At the heart of Featurespace's products are novel statistical algorithms. These algorithms are based on Bayesian inference and modern machine learning techniques that originate from the founders' state of the art research at Cambridge University. Featurespace is rapidly expanding. It is head-hunting talented engineers, sales people and marketers.
GenDrive - www.gendrive.co.ukGenDrive was set up in 2005 to develop groundbreaking, real-world technology able to capture energy from any renewable power source and then feed that energy into the grid. The result is a range of ‘Plug and Play’ grid connected inverters designed from the outset to be easy to install and service, keeping capital and ongoing costs to a minimum. The units can be re-configured simply and automatically, for connection to a wide range of renewable energy devices. The GenDrive Totus Wind TW 3-10 turbine’s low cut-in voltage and flexible nature guarantees optimised turbine performance. The advanced platform provides turbine control functionality with analogue and digital signal input measurement and control signal output, for real-world system integration. The unit’s array of communication protocols including CAN and wireless GPRS, means that remote monitoring, inverter set-up and data logging, can all be achieved.
Inotec AMD Ltd - www.inotecamd.comTreating wounds consumes five per cent of total healthcare budgets. Growing numbers of people, especially the elderly, suffer painful, debilitating wounds for five years or more. Oxygen is key to wound healing. Inotec in Cambridge used fuel cell technology to develop a system to promote healing of wounds not treated effectively by existing technology. It uses a miniaturised portable generator to feed moist oxygen to the wound 24/7 whilst the patient goes about their daily life. Inotec successfully completed a first clinical trial in February 2010 and has brought patient benefit in further case studies.
Oval Medical Technologies Ltd - www.ovalmedical.comOval Medical Technologies Ltd is developing the next generation of autoinjectors and is accelerating commercialisation of the technology. Business Weekly reported before Christmas 2010 that Oval was seeking new funding – and a second oversubscribed funding round was duly completed early in 2011. This was again led by The Cambridge Angels, with participation from Cambridge Capital Group, Team Consulting, and a number of new investors. CEO Matt Young said the company had made substantial progress, since its first funding round in February 2010, in developing the next generation of autoinjector technology, which will revolutionise the Oval’s use of cyclic olefin plastic, rather than traditional glass, has facilitated the development of a primary drug container that is particularly well suited for sensitive biological drugs. The design also eliminates many contamination issues and has a superior user interface. As a result, several large pharmaceutical companies have shown substantial interest in working with Oval and undertaking feasibility studies with a view to utilising the technology for a variety of injectable drugs.
Phico Therapeutics - www.phicotherapeutics.co.ukDr Heather Fairhead founded Phico Therapeutics with seed funding from Cambridge Research and Innovation Limited (CRIL). The company has since raised approximately £9 million, including UK government grants of £350,000 and investment from institutional investors and Business Angels. Phase I and Phase II clinical trials with Phico’s first product, SASPject™ PT1.2 are funded by a Strategic Translation Award of just over £1 million from The Wellcome Trust. Phico Therapeutics has given oral and poster presentations at major conferences around the world. Based at the Babraham Bioincubator near Cambridge and employs a team of 14, including nine full-time, post-doctoral scientists. It is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called superbugs.
Pneumacare - www.pneumacare.comPneumaScan’s dynamic-3D-imaging approach provides novel information and a fresh clinical perspective. The company provides clinicians with non–contact, intelligent monitoring of vital signs in clinical, intensive care and home care applications. The non-invasive PneumaScan platform allows monitoring of a broader portion of the population while reducing the potential of cross infection. Future products will offer monitoring capabilities putting anaesthetised post-operative patients and neonatal babies in incubators within reach. Clinical interest in PneumaCare’s approach began with Richard Iles addressing the needs voiced by his colleges for a non-invasive respiratory assessment technique for small children. Working with Cambridge University the idea has grown into a body of presentations, publications and evidence based on demonstrations in Addenbrooke’s Hospital Cambridge and an extended presence in Great Ormond Street Hospital London. Cambridge University Engineering Department is collaborating with PneumaCare in the development of the device and components, data capture systems, modelling and analysis. A collaborative agreement with Plextek Ltd., a shareholder in Pneumacare, provides the expertise and engineering processes required to develop the technology into a commercial system ready for large-scale manufacture.
Urosens - www.urosens.comUroSens develops and commercialises point-of-care tests for cancers of the urinogenitary tract for use in the urology clinic or doctor's surgery. The initial target is bladder cancer, the fifth most common cancer in the UK with the highest recurrence rate of any malignancy. The company's key technology provides a highly sensitive and specific test, based on intellectual property exclusively licensed from Cancer Research Technology Ltd, the technology transfer arm of Cancer Research UK. The current gold standard test for bladder cancer is cystoscopy, an invasive and expensive endoscopic procedure. UroSens' test, under development, requires only a sample of urine which is analysed for the presence of a specific protein using a highly sensitive potentiometric detection system. The test matches closely the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.